Topic Genentech

News Genentech

• Genmab announces patent settlement agreement for ofatumumab

  Genmab A/S announced that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab’s development and commercial collaborator f more

• Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody

  NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated at NovImm more

• Galapagos and Genentech extend drug discovery collaboration

  Galapagos NV announced that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group.  Total potential value of the contract extension is up to £21.5 million (€23.4 million). This is the third such extension since the agre more

Publications Genentech

• Single‐ and Multiple‐Dose Intravenous and Oral Pharmacokinetics of the Hedgehog Pathway Inhibitor Vismodegib in Healthy Female Subjects

  SUMMARY AIM:  Vismodegib has demonstrated clinical activity in patients with advanced basal cell carcinoma; the pharmacokinetics (PK) of vismodegib is nonlinear. The objective of this study was to determine whether vismodegib PK changes following repeated dosing by administering a tracer intraven more

• Ligand Binding Assays in the 21st Century Laboratory: Automation

  Ligand Binding Assays in the 21st Century Laboratory: Automation Content Type Journal Article Category Commentary Pages 1-12 DOI 10.1208/s12248-012-9323-z Authors Ago B. Ahene, XOMA Corporation, 2710 Seventh Street, Berkeley, California 94710, USA Chris Morrow, Genentech, South San Fra more

• Ligand Binding Assays in the 21st Century Laboratory: Platforms

  Ligand Binding Assays in the 21st Century Laboratory: Platforms Content Type Journal Article Category Commentary Pages 1-6 DOI 10.1208/s12248-012-9321-1 Authors Franklin P. Spriggs, Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., 1 Burtt Road, MS G2002, Andover, more

Market studies Genentech

• Acute Coronary Syndrome (ACS) Drug Market Prospects 2011-2021

  What are the commercial prospects for the pharmacological treatment of acute coronary syndrome? Our new report shows you its revenue potential from 2011 to 2021. We predict and explain the commercial opportunities in that industry and market. Our report gives you revenue forecasts to 2021 for treat more

• F. Hoffmann-La Roche Ltd: PharmaVitae Profile

  Introduction This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs Fea more

• Pacific Edge Limited (PEB) - Product Pipeline Analysis

  Pacific Edge Limited (PEB) - Product Pipeline Analysis Summary This report is a source for data, analysis and actionable intelligence on the Pacific Edge Limited portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the d more

Websites Genentech